Adrenergic Neurotransmission and Norepinephrine Physiology

Adrenergic neurotransmission is the chemical signalling used by most postganglionic sympathetic neurons, which release the catecholamine norepinephrine onto adrenergic receptors on target cells. Together with epinephrine released from the adrenal medulla, this system mediates the cardiovascular, metabolic, and smooth-muscle effects of sympathetic activation. The diversity of adrenergic receptor subtypes allows the same transmitter to produce different, even opposite, effects in different tissues.

Definition

Adrenergic neurotransmission is the process by which norepinephrine (and circulating epinephrine) is synthesized, released, and acts on alpha- and beta-adrenergic receptors to mediate sympathetic effects, with transmission terminated mainly by neuronal reuptake and enzymatic degradation.

Scope

This topic covers the synthesis, release, receptor action, and termination of norepinephrine in the sympathetic nervous system: catecholamine biosynthesis, the classification of adrenergic receptors into alpha and beta families and their subtypes, the second-messenger pathways they engage, and the mechanisms (reuptake and enzymatic breakdown) that end transmission. It is reference physiology, not clinical guidance or drug-dosing information.

Core questions

• How is norepinephrine synthesized, stored, and released by sympathetic nerve terminals?
• What are the alpha and beta adrenergic receptor subtypes and which signalling pathways do they use?
• How does the same transmitter produce different effects in different organs?
• How is adrenergic signalling terminated?

Key concepts

• Norepinephrine and epinephrine (catecholamines)
• Catecholamine biosynthesis (tyrosine to dopamine to norepinephrine)
• Alpha-1, alpha-2, beta-1, beta-2, and beta-3 adrenergic receptors
• G-protein-coupled receptor signalling
• Neuronal reuptake (norepinephrine transporter)
• Enzymatic degradation (monoamine oxidase, catechol-O-methyltransferase)
• Adrenal medullary catecholamine release
• Tissue-specific (subtype-dependent) responses

Key theories

Alpha and beta adrenergic receptor classification

Ahlquist proposed that the diverse and sometimes opposite responses to adrenergic agonists could be explained by two distinct receptor types, alpha and beta, distinguished by their relative sensitivities to a series of catecholamines; this framework remains the basis of adrenergic receptor pharmacology and physiology.

Mechanisms

Sympathetic terminals synthesize norepinephrine from tyrosine through dopa and dopamine, store it in vesicles, and release it on depolarization. Norepinephrine acts on adrenergic receptors, all of which are G-protein-coupled: alpha-1 receptors typically couple to Gq and raise intracellular calcium (for example, vascular smooth-muscle contraction); alpha-2 receptors couple to Gi and reduce cyclic AMP, including presynaptic autoreceptors that inhibit further release; beta-1, beta-2, and beta-3 receptors couple to Gs and raise cyclic AMP, producing effects such as increased cardiac rate and contractility (beta-1) or smooth-muscle relaxation in airways and vessels (beta-2). Because tissues express different subtype mixtures, one transmitter yields organ-specific responses, an insight rooted in Ahlquist's two-receptor classification (Ahlquist, 1948). Transmission is terminated mainly by reuptake into the nerve terminal via the norepinephrine transporter and by enzymatic degradation through monoamine oxidase and catechol-O-methyltransferase (Kandel et al., 2021; Boron & Boulpaep, 2017).

Clinical relevance

Adrenergic physiology explains how the sympathetic system raises heart rate and blood pressure, redistributes blood flow, and mobilizes energy, and it provides the conceptual basis for understanding many cardiovascular and respiratory drug classes. This entry is descriptive physiology and not a basis for individual treatment or dosing decisions.

Evidence & guidelines

The receptor classification and signalling described here derive from Ahlquist's classic work (1948) and are consolidated in standard physiology and neuroscience texts (Kandel et al., 2021; Boron & Boulpaep, 2017). As reference physiology the topic is not the subject of clinical guidelines.

History

Walter Cannon's early-twentieth-century work established the sympathetic system's role in mobilizing the body and pointed to a catecholamine-like 'sympathin' as its chemical mediator (Cannon, 1929); the transmitter was later identified as norepinephrine. Raymond Ahlquist's 1948 study introduced the division of adrenergic responses into alpha and beta receptor types, which reframed adrenergic physiology and pharmacology and remains foundational (Ahlquist, 1948).

Key figures

• Raymond P. Ahlquist
• Walter B. Cannon
• Ulf von Euler

Seminal works

• ahlquist-1948
• cannon-1929

Frequently asked questions

Why can norepinephrine cause both contraction and relaxation of smooth muscle?

Because different tissues express different adrenergic receptor subtypes: alpha-1 receptors generally promote contraction while beta-2 receptors promote relaxation, so the same transmitter produces opposite effects depending on which receptor predominates.

How is norepinephrine signalling switched off?

Mainly by reuptake of norepinephrine back into the nerve terminal through the norepinephrine transporter, with enzymatic breakdown by monoamine oxidase and catechol-O-methyltransferase accounting for further inactivation.